z-logo
open-access-imgOpen Access
<p>HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial–Mesenchymal Transition</p>
Author(s) -
Huachen Song,
Xiaonan Tang,
Xiang Li,
Yufei Wang,
AnJun Deng,
Wenjie Wang,
HaiJing Zhang,
HaiLin Qin,
LiWei Wu
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s262806
Subject(s) - epithelial–mesenchymal transition , mesenchymal stem cell , cancer research , in vivo , chemistry , western blot , carcinogenesis , cancer , metastasis , biology , pathology , medicine , biochemistry , microbiology and biotechnology , gene
Colitis-associated cancer (CAC) accounts for approximately 15% of IBD patient mortalities. However, currently available anti-CAC drugs possess many disadvantages including safety, specificity and side effects. Therefore, the development of novel anti-CAC compounds is imperative. HLJ2 was a monomeric compound synthesized by our institute and reported to have an effect on ulcer colitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here